collection
MENU ▼
Read by QxMD icon Read
search

Kidney transplantation: immunosuppressive therapy

shared collection
5 papers 0 to 25 followers
By P O Pediatrics, Nephrology
https://www.readbyqxmd.com/read/26121616/long-term-follow-up-of-de-novo-use-of-mtor-and-calcineurin-inhibitors-after-kidney-transplantation
#1
Mayara Ivani de Paula, José Osmar Medina Pestana, Alexandra Nicolau Ferreira, Marina Pontello Cristelli, Marcello Fabiano Franco, Wilson Ferreira Aguiar, Hélio Tedesco-Silva, Claudia Rosso Felipe
BACKGROUND: Long-term efficacy and safety of de novo use of the mammalian target of rapamycin inhibitors (mTORi) have been evaluated primarily using registry data. METHODS: This was a pooled retrospective analysis of data obtained from 10 prospective randomized trials in de novo kidney transplant recipients (n = 581) receiving calcineurin inhibitors (CNIs) combined with sirolimus (n = 329), everolimus (n = 128), or antimetabolites (n = 124). RESULTS: There were no differences in patient (84...
February 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/26126806/mtor-inhibitor-versus-mycophenolic-acid-as-the-primary-immunosuppression-regime-combined-with-calcineurin-inhibitor-for-kidney-transplant-recipients-a-meta-analysis
#2
COMPARATIVE STUDY
Xishao Xie, Yan Jiang, Xiuxiu Lai, Shilong Xiang, Zhangfei Shou, Jianghua Chen
BACKGROUND: A number of studies have provided information regarding the risks and benefits of mammalian target of rapamycin inhibitors (mTOR-I) combined with calcineurin inhibitors (CNI) versus mycophenolic acid (MPA). METHODS: Medline, Embase and the Cochrane Central Register of Controlled Trials were searched. Randomized controlled trials comparing mTOR-I to MPA as the primary immunosuppressive regimen in combination with CNI were selected and meta-analyzed. RESULTS: Eleven randomized controlled trials consisting of 4930 patients in total were included...
July 1, 2015: BMC Nephrology
https://www.readbyqxmd.com/read/26281138/improved-long-term-survival-in-kidney-transplant-recipients-with-donor-specific-hla-antibodies-after-mycophenolic-acid-escalation
#3
Lorita M Rebellato, Karen Parker, Matthew J Everly, Kimberly P Briley, William Kendrick, Scott Kendrick, Carl E Haisch, Paul I Terasaki, Paul Bolin
The development of donor specific antibodies (DSA) post transplant has been associated with chronic rejection and graft failure. In a longitudinal study, we have shown that increases in DSA precede rejection by months, thus allowing time for intervention. We hypothesized that mycophenolic acid (MPA) dose increases may reduce and/or stabilize DSA strength and also preserve renal function. Thirty stable DSA positive kidney transplant recipients participated in this Institutional Review Board approved, exploratory, open-label, single center study to assess the efficacy of MPA dose escalation in patients with DSA...
2014: Clinical Transplants
https://www.readbyqxmd.com/read/26457257/induction-by-anti-thymocyte-globulins-in-kidney-transplantation-a-review-of-the-literature-and-current-usage
#4
REVIEW
Paolo Malvezzi, Thomas Jouve, Lionel Rostaing
CONTEXT: Preventing acute rejection (AR) after kidney transplantation is of utmost importance because an AR can have a negative impact on long-term allograft survival. EVIDENCE ACQUISITION: Directory of Open Access Journals (DOAJ), Google Scholar, PubMed, EBSCO, and Web of Science have been searched. RESULTS: At the moment this can be done by using rabbit anti-thymocyte globulins (rATGs) as an induction therapy. However, because rATGs are associated with some deleterious side-effects, such as the opportunistic infections cytomegalovirus (CMV) and de novo post-transplant cancer, it is very important they are used optimally, i...
October 2015: Journal of Nephropathology
https://www.readbyqxmd.com/read/26633102/mycophenolic-acid-versus-azathioprine-as-primary-immunosuppression-for-kidney-transplant-recipients
#5
REVIEW
Martin Wagner, Amy K Earley, Angela C Webster, Christopher H Schmid, Ethan M Balk, Katrin Uhlig
BACKGROUND: Modern immunosuppressive regimens after kidney transplantation usually use a combination of two or three agents of different classes to prevent rejection and maintain graft function. Most frequently, calcineurin-inhibitors (CNI) are combined with corticosteroids and a proliferation-inhibitor, either azathioprine (AZA) or mycophenolic acid (MPA). MPA has largely replaced AZA as a first line agent in primary immunosuppression, as MPA is believed to be of stronger immunosuppressive potency than AZA...
December 3, 2015: Cochrane Database of Systematic Reviews
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"